Nanjing Vishee Medical Technology Co., Ltd (SHA:688580)
37.97
-0.79 (-2.04%)
Nov 13, 2026, 3:00 PM CST
SHA:688580 Revenue
Nanjing Vishee Medical Technology had revenue of 98.49M CNY in the quarter ending September 30, 2026, a decrease of -14.41%. This brings the company's total for the last twelve months to 462.13M, up 6.52% year-over-year. In the year 2025, Nanjing Vishee Medical Technology had annual revenue of 462.73M with 15.66% growth. That makes Nanjing Vishee Medical Technology the 25,523rd largest company in the world by revenue and 4,534th in China.
Revenue (ttm)
462.13M
Revenue Growth
+6.52%
P/S Ratio
7.86
Revenue / Employee
727.76K
Employees
636
Market Cap
3.63B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full SHA:688580 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 462.73M | 62.67M | 15.66% |
| Dec 31, 2024 | 400.06M | -62.16M | -13.45% |
| Dec 31, 2023 | 462.22M | 140.60M | 43.72% |
| Dec 31, 2022 | 321.62M | -108.42M | -25.21% |
| Dec 31, 2021 | 430.04M | 51.68M | 13.66% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Wuhan Huakang Century Clean Technology | 2.63B |
| Guangdong Biolight Meditech | 1.12B |
| Getein Biotech | 1.11B |
| Zhejiang Orient Gene Biotech | 993.10M |
| Shanghai Aohua Photoelectricity Endoscope | 806.07M |
| Ningbo David Medical Device | 612.67M |
| Hangzhou AGS MedTech | 547.63M |
| Beijing Leadman Biochemistry | 485.94M |